Ironwood Lifts 2026 Guidance Again as Q3 Revenue Reaches $133M and Adjusted EBITDA Hits $98M
IRWD has more than doubled off its 52-week low of $1.76.
Summary
Ironwood raised full-year 2026 guidance for the second consecutive quarter after Q3 revenue of $133.0 million, GAAP net income of $59.8 million and record adjusted EBITDA of $97.9 million, and paid down $60.0 million of revolver debt.
Key Events · Earnings and Guidance · IRWD
-
Q3 Revenue and Profit Grow
Total revenue came in at $133.0 million versus $122.1 million a year ago, with GAAP net income of $59.8 million, or $0.36 per share, and record adjusted EBITDA of $97.9 million versus $81.8 million.
-
Full-Year Guidance Raised Again
U.S. LINZESS net sales guidance was lifted to $1.20-$1.25 billion from $1.15-$1.20 billion, total revenue to $485-$510 million from $460-$485 million, and adjusted EBITDA to greater than $350 million from greater than $310 million.
-
LINZESS Sales and Margin Improve
Q3 LINZESS U.S. net sales were $324.9 million, up 3.2% year-over-year on 4.9% prescription demand growth, with commercial margin at 79.8% versus 75.9% and Ironwood's share of net profit at $129.6 million.
-
Debt Paydown and Cash Position
Operating cash flow of $130.8 million funded a $60.0 million repayment on the revolving credit facility, leaving $325.0 million outstanding and $225.0 million of remaining capacity, against $86.4 million of cash at September 30, 2026.
Analysis · IRWD · Life Sciences
For the second straight quarter, Ironwood beat its own August targets and raised full-year guidance: U.S. LINZESS net sales are now guided to $1.20-$1.25 billion (from $1.15-$1.20 billion), total revenue to $485-$510 million (from $460-$485 million), and adjusted EBITDA to more than $350 million (from more than $310 million). The quarter delivered $133.0 million of revenue, $59.8 million of GAAP net income ($0.36 per share) and record adjusted EBITDA of $97.9 million, while LINZESS U.S. net sales of $324.9 million rose 3.2% year-over-year on 4.9% prescription demand growth. Cash generation stood out: $130.8 million from operations in the quarter funded a $60.0 million paydown on the revolver, leaving $325.0 million outstanding and $225.0 million available. The offset is a thinner cash cushion of $86.4 million against $132.7 million of receivables, and the apraglutide STARS-2 confirmatory trial remains a 2029 filing story, so near-term value still rests entirely on LINZESS profit share.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRWD was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $623M. The 52-week trading range was $1.76 to $5.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.